GLP-1 RA drugs show cancer risk reduction but weight regain after cessation
Jun 03, 2026
GLP-1 receptor agonists combined with progestin therapy significantly reduce endometrial cancer risk in women with uterine hyperplasia, according to a JAMA Network Open study. A separate meta-analysis finds patients regain 60% of weight lost one year after stopping GLP-1 RAs, with weight regain plateauing at 75.3% of treatment loss.